EQUULUS Therapeutics is a neuroscience biotech dedicated to transforming the treatment landscape for central nervous system (CNS) disorders across psychiatric, neurologic and addiction disorders. Founded with the collaboration of leading experts in neuroscience exploration and development, EQUULUS Therapeutics is comprised of a highly accomplished team from academia, biotech and pharmaceutical sectors. Innovation and precision drive the company, which has established a specialized network of partners to execute a streamlined and efficient development approach. This process, honed over decades of collective experience, ensures both time and capital efficiency in the pursuit of transformational therapeutics.

Equulus takes a transdiagnostic approach to the development of therapeutics for CNS disorders, which involves identifying and targeting fundamental factors that transcend standard diagnostic categories and are tied to clear disease driving physiology. This approach is supported by evidence that mental health disorders are composed of clusters of symptoms that vary between patients and overlap with other disorders. Focusing on the key criteria and underlying mechanisms of CNS disorders allows us to get below the surface of the symptoms and address the crucial origin of the disease. In parallel, Equulus is working towards the development and application of biomarkers to aid in drug development. Doing so will increase development success rates and generate highly valued therapeutics that more completely treat the target disorders. The company applies its expertise in novel drug formulations and drug delivery approaches to each program to maximize drug efficacy and product value.

EQUULUS Therapeutics

Org chart

Teams

Offices